ArticleBMC infectious diseases2026
Evolving profiles and treatment success predictors among tuberculosis patients in Uganda from 2019 to 2023: a registry based study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluating tuberculosis treatment outcomes and predictors in five Southern African countries: A multi-country cohort analysis.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThere is a need to evaluate evolving trends in tuberculosis (TB) patient profiles, treatment outcomes and treatment success determinants, which this study assessed over a five-year period (2019–2023).
methodsWe conducted a single site registry based study analysing TB patient data from 2019 to 2023, involving 1,051 tuberculosis patients who initiated treatment at Mildmay Uganda Hospital. Descriptive statistics summarized demographics and clinical characteristics, and annual cohort comparisons assessed changes over time. Treatment success was defined as cured or completed treatment. Chi-square, Fisher’s exact and logistic regression identified factors associated with treatment outcomes, with significance set at p < 0.05.
resultsAmong 1,051 participants, most were male (55.2%), aged 34–50 years (40.8%), HIV-positive (72.1%), and residents of the Kampala Metropolitan Area (84.9%). Pulmonary TB was predominant, with 58.2% bacteriologically confirmed cases. Patient profiles included 91.0% new cases, 7.0% relapses, 0.6% failures, and 1.4% lost to follow-up. Relapse rose significantly from 0.7% in 2019 to 14.6% in 2023 (p < 0.001), while the proportion of new cases declined. Treatment outcomes also varied: cure rates improved steadily, reaching 65.7% in 2023, whereas treatment completion declined from 61.3% in 2019 to 22.6% in 2023. Mortality peaked at 10.2% in 2022, and treatment failure was highest in 2021 (2.7%).Unsuccessful outcomes were linked with, older age (≥ 50 years) (aOR = 3.66; 95% CI: 1.27–10.55; p = 0.016), being separated, divorced, or widowed (aOR = 1.86; 95% CI: 1.08–3.22; p = 0.027), and prior TB treatment failure (aOR = 18.45; 95% CI: 3.36–101.40; p = 0.001).
conclusionThis study demonstrates a shifting trend in TB patient profiles, with a notable increase in relapses over time. Unsuccessful treatment outcomes were associated with age ≥ 50 years, prior treatment failure, and being separated, divorced, or widowed. Strengthening post-treatment follow-up, adherence support is essential. Further prospective research on evolving TB patient profiles and treatment outcomes is critical to inform targeted interventions and optimize TB control strategies. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.